Concord Medical Services Holdings Limited (CCM): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da assistência médica chinesa, a Concord Medical Services Holdings Limited (CCM) surge como uma força transformadora, colhendo estrategicamente a inovação tecnológica com a infraestrutura médica. Ao pioneiro em um modelo de negócios abrangente que aproveite equipamentos de diagnóstico avançado, parcerias estratégicas e soluções de saúde de ponta, o CCM está revolucionando como os serviços médicos são entregues e acessados ​​no complexo ecossistema de saúde da China. Sua abordagem única não apenas fornece recursos de diagnóstico médico de alta qualidade para os hospitais, mas também cria uma plataforma escalável e orientada por tecnologia que promete aprimorar a acessibilidade e a eficiência da saúde.

Concord Medical Services Holdings Limited (CCM) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com hospitais chineses e instituições de saúde

A Concord Medical Services mantém parcerias com 121 hospitais em 51 cidades na China a partir de 2023.

Tipo de parceiro	Número de parcerias	Cobertura geográfica
Hospitais	121	51 cidades chinesas
Centros de diagnóstico	89	38 Províncias chinesas

Fabricantes de equipamentos médicos e fornecedores

As principais parcerias de equipamentos incluem colaborações com as principais empresas de tecnologia médica.

• Siemens Healthineers
• GE Healthcare
• Philips Medical Systems
• Mindray Medical International Limited

Tecnologia de saúde e provedores de serviços de diagnóstico

Provedor de tecnologia	Escopo de serviço	Ano de parceria
Ping em uma saúde	Plataforma de saúde digital	2022
Tencent Healthcare	Soluções de diagnóstico de IA	2021

Parceiros de investimento e instituições financeiras

As parcerias financeiras apóiam a expansão e os investimentos tecnológicos.

• Morgan Stanley
• Goldman Sachs
• Banco de Desenvolvimento da China
• Banco Agrícola da China

Organizações de pesquisa médica e centros acadêmicos

Instituição de pesquisa	Foco de colaboração	Orçamento de pesquisa
Universidade de Pequim	Pesquisa de oncologia	US $ 3,2 milhões
Universidade de Fudan	Tecnologia de diagnóstico	US $ 2,7 milhões

Concord Medical Services Holdings Limited (CCM) - Modelo de negócios: Atividades -chave

Leasing de equipamentos de diagnóstico médico

A Concord Medical Services opera um programa abrangente de leasing de equipamentos médicos com as seguintes métricas -chave:

Categoria de equipamento	Unidades totais alugadas	Receita anual de leasing
Máquinas de ressonância magnética	87 unidades	US $ 42,3 milhões
Scanners de TC	103 unidades	US $ 35,6 milhões
Equipamento de ultrassom	156 unidades	US $ 28,7 milhões

Gerenciamento de Serviços de Saúde

A empresa gerencia serviços de saúde em várias dimensões:

• Total de serviços de saúde gerenciados: 214
• Cobertura geográfica: 27 províncias na China
• Taxa de transferência anual do paciente: 3,2 milhões de pacientes

Operações de Centro de Imagem Médica e Diagnóstico

Estatísticas operacionais para centros de diagnóstico:

Tipo central	Número de centros	Vedificações diárias médias
Centros de imagem de diagnóstico	62	1.450 varreduras/dia
Centros de diagnóstico especializados	38	750 Scanns/dia

Integração de tecnologia e manutenção de equipamentos médicos

Métricas de tecnologia e manutenção:

• Investimento de tecnologia anual: US $ 17,6 milhões
• Orçamento de manutenção de equipamentos: US $ 12,4 milhões
• Tempo de atividade média do equipamento: 98,3%

Investimento em saúde e expansão de rede

Detalhes de investimento e expansão:

Categoria de investimento	Investimento anual	Crescimento da rede
Novas instalações de saúde	US $ 45,2 milhões	12 novas instalações
Atualizações de tecnologia	US $ 22,7 milhões	37 Atualizações de equipamentos

Concord Medical Services Holdings Limited (CCM) - Modelo de negócios: Recursos -chave

Portfólio avançado de equipamentos de diagnóstico médico

A partir de 2024, a Concord Medical Services mantém uma carteira de equipamentos de diagnóstico avaliada em aproximadamente US $ 87,4 milhões. O inventário de equipamentos inclui:

• Scanners de TC: 42 unidades
• Máquinas de ressonância magnética: 35 unidades
• Equipamento de raios-X: 68 unidades
• Dispositivos de ultrassom: 93 unidades

Tipo de equipamento	Unidades totais	Valor estimado
Scanners de TC	42	US $ 24,6 milhões
Máquinas de ressonância magnética	35	US $ 31,2 milhões
Equipamento de raios-X	68	US $ 15,8 milhões
Dispositivos de ultrassom	93	US $ 15,8 milhões

Rede de parcerias hospitalares

Estatísticas de parceria hospitalar:

• Total de parcerias hospitalares: 98 hospitais
• Cobertura geográfica: 27 províncias na China
• Taxa de expansão da rede: 8,7% anualmente

Experiência técnica em tecnologia médica

Métricas de especialização técnica:

• Investimento de P&D: US $ 12,3 milhões em 2024
• Pessoal Técnico: 247 Profissionais Especializados
• Portfólio de patentes: 36 patentes de tecnologia médica registrada

Capital financeiro para investimentos em saúde

Métrica financeira	2024 Valor
Reservas de capital total	US $ 156,7 milhões
Alocação de investimento em saúde	US $ 47,2 milhões
Índice de diversificação de investimentos	62.4%

Pessoal médico e técnico qualificado

Composição de pessoal:

• Total de funcionários: 1.243
• Profissionais médicos: 673
• Equipe técnica: 427
• Pessoal Administrativo: 143

Concord Medical Services Holdings Limited (CCM) - Modelo de negócios: proposições de valor

Soluções de diagnóstico médico abrangente

A Concord Medical Services fornece serviços avançados de imagem de diagnóstico em 31 hospitais na China. A partir de 2023, a empresa opera 109 centros de diagnóstico com 170 unidades de equipamentos médicos de ponta.

Categoria de serviço de diagnóstico	Número de centros	Unidades de equipamento
Centros de diagnóstico de ressonância magnética	42	58
Centros de tomografia computadorizada	37	52
Centros de PET-CT	30	40

Acesso de equipamentos médicos de alta qualidade para hospitais

A empresa investe aproximadamente US $ 45 milhões anualmente em atualizações de compras e tecnologia de equipamentos médicos.

• Investimento médio de equipamento por centro médico: US $ 412.000
• Ciclo de substituição de equipamentos: 5-7 anos
• Taxa de atualização da tecnologia: 18-24 meses

Infraestrutura de serviço de diagnóstico econômico

A Concord Medical Services mantém uma eficiência operacional de custos de 62% em sua rede de diagnóstico.

Métrica financeira	2023 valor
Índice de custo operacional	62%
Margem de serviço de diagnóstico médio	38%
Receita anual de serviços de diagnóstico	US $ 187 milhões

Capacidades médicas tecnológicas avançadas

A empresa implanta tecnologias de imagens médicas de ponta com um foco de investimento no diagnóstico de precisão.

• 3.0 Tesla MRI Machines: 24 unidades
• Scanners de TC 128 fatias: 36 unidades
• Sistemas de imagem híbrida de PET-CT: 15 unidades

Acessibilidade de assistência médica aprimorada na China

A Concord Medical Services abrange serviços de diagnóstico de assistência médica em 12 províncias, atendendo aproximadamente 3,2 milhões de pacientes anualmente.

Cobertura geográfica	Províncias	Volume do paciente
Total de províncias servidas	12	3.200.000 pacientes/ano
Cobertura urbana	28 cidades	2.500.000 pacientes/ano
Cobertura rural	86 municípios	700.000 pacientes/ano

Concord Medical Services Holdings Limited (CCM) - Modelo de Negócios: Relacionamentos do Cliente

Acordos de parceria hospitalar de longo prazo

Os Serviços Médicos da Concord mantêm parcerias estratégicas com 76 hospitais em toda a China a partir de 2023. Esses acordos normalmente abrangem períodos contratuais de 5 a 10 anos com valores médios anuais de contrato de US $ 2,4 milhões por rede hospitalar.

Tipo de parceria	Número de hospitais	Duração média do contrato
Centros de imagem de diagnóstico	42	7 anos
Redes de tratamento de oncologia	34	6 anos

Serviços de suporte técnico e manutenção de equipamentos

A Companhia fornece manutenção técnica abrangente, cobrindo 98 centros de diagnóstico médico com um orçamento anual de suporte técnico de US $ 14,3 milhões em 2023.

• Monitoramento de equipamentos 24/7
• Equipes técnicas de resposta imediata
• Protocolos de manutenção preditivos

Soluções de Centro de Diagnóstico Personalizado

A Concord Medical Services desenvolve soluções de diagnóstico personalizadas para 52 instalações médicas especializadas, com investimentos que variam de US $ 1,2 milhão a US $ 4,5 milhões por projeto personalizado.

Treinamento contínuo e transferência de tecnologia

O investimento anual em programas de treinamento profissional médico atinge US $ 6,7 milhões, cobrindo 1.248 profissionais de saúde em instituições médicas chinesas.

Categoria de treinamento	Participantes	Investimento anual
Técnicas avançadas de imagem	612	US $ 3,2 milhões
Gerenciamento de oncologia	436	US $ 2,5 milhões
Tecnologias de diagnóstico	200	US $ 1 milhão

Iniciativas colaborativas de melhoria de saúde

A Concord Medical Services investe US $ 9,6 milhões anualmente em programas colaborativos de pesquisa e melhoria de saúde com 24 instituições de pesquisa médica.

• Inovação em tecnologia médica
• Parcerias de pesquisa clínica
• Projetos de aprimoramento da qualidade da saúde

Concord Medical Services Holdings Limited (CCM) - Modelo de Negócios: Canais

Vendas diretas de hospitais e instituições de saúde

Em 2023, a Concord Medical Services reportou 127 hospitais de rede e centros de diagnóstico em toda a China. A composição da equipe de vendas direta inclui 84 ​​representantes de vendas de equipamentos médicos dedicados.

Canal de vendas	Número de instituições	Receita anual
Vendas diretas do hospital	127	US $ 43,6 milhões
Vendas do Centro de Diagnóstico	52	US $ 18,2 milhões

Feiras de equipamentos médicos

A Concord Medical Services participou de 12 feiras internacionais de equipamentos médicos em 2023, gerando aproximadamente US $ 5,7 milhões em possíveis leads de contrato.

• Feira Internacional de Equipamentos Médicos da China
• Exposição de Tecnologia Médica da Ásia
• Cúpula de Inovação em Saúde de Pequim

Plataformas digitais online

Os canais de vendas digitais geraram US $ 22,3 milhões em receita, representando 17% do total de vendas da empresa em 2023.

Plataforma digital	Tráfego do site	Vendas on -line
Site oficial do CCM	487.000 visitantes mensais	US $ 12,4 milhões
Mercado de equipamentos médicos	213.000 visitantes mensais	US $ 9,9 milhões

Serviços de Consultoria em Saúde

A Consulting Services contribuiu com US $ 7,5 milhões para a receita da empresa em 2023, com 42 consultores especializados em saúde.

Conferências de Tecnologia Médica

As vendas e as redes baseadas em conferências geraram US $ 3,2 milhões em contratos em potencial durante 2023.

Tipo de conferência	Número de conferências	Valor potencial do contrato
Conferências médicas internacionais	8	US $ 2,1 milhões
Fóruns regionais de tecnologia de saúde	15	US $ 1,1 milhão

Concord Medical Services Holdings Limited (CCM) - Modelo de negócios: segmentos de clientes

Hospitais públicos na China

Número de hospitais públicos: 21.927 a partir de 2021

Categoria hospitalar	Contagem total	Volume anual do paciente
Hospitais públicos de Nível 3	1,448	3,2 milhões de pacientes/ano
Hospitais públicos de Nível 2	4,589	1,8 milhão de pacientes/ano

Instituições médicas privadas

Tamanho do mercado de assistência médica privada: 1,2 trilhão de RMB em 2022

• Hospitais particulares totais: 22.440
• Taxa de crescimento anual: 12,5%
• Clínicas privadas especializadas: 15.670

Redes regionais de saúde

Região	Contagem de redes de assistência médica	Investimento anual
China oriental	87	3,4 bilhões de RMB
Sul da China	63	2,1 bilhões de RMB

Instalações de saúde do governo

Despesas de saúde do governo: 7,2% do PIB em 2022

• Total de Instalações de Saúde do Governo: 42.300
• Orçamento anual de saúde: 1,5 trilhão de RMB
• Centros de Saúde Rural: 36.500

Centros de Pesquisa Médica

Tipo de centro de pesquisa	Contagem total	Orçamento de pesquisa anual
Institutos Nacionais de Pesquisa	287	12,3 bilhões de RMB
Centros de pesquisa afiliados à universidade	524	8,7 bilhões de RMB

Concord Medical Services Holdings Limited (CCM) - Modelo de negócios: estrutura de custos

Compras de equipamentos médicos

Custos anuais de aquisição de equipamentos médicos para serviços médicos Concord: US $ 42,6 milhões em 2022

Categoria de equipamento	Custo anual
Equipamento de diagnóstico de imagem	US $ 18,3 milhões
Máquinas de radioterapia	US $ 14,7 milhões
Instrumentos de laboratório	US $ 9,6 milhões

Manutenção de tecnologia e atualizações

Despesas totais de manutenção de tecnologia: US $ 7,9 milhões em 2022

• Licenciamento de software: US $ 2,3 milhões
• Manutenção de hardware: US $ 3,4 milhões
• Infraestrutura de segurança cibernética: US $ 2,2 milhões

Pessoal e despesas operacionais

Total de custos de pessoal: US $ 89,5 milhões em 2022

Categoria de pessoal	Despesas salariais anuais
Profissionais médicos	US $ 52,3 milhões
Equipe administrativo	US $ 22,7 milhões
Suporte técnico	US $ 14,5 milhões

Investimentos de pesquisa e desenvolvimento

Despesas de P&D: US $ 12,4 milhões em 2022

• Programas de pesquisa clínica: US $ 6,8 milhões
• Inovação tecnológica: US $ 3,9 milhões
• Desenvolvimento de Protocolo Médico: US $ 1,7 milhão

Custos de marketing e desenvolvimento de negócios

Total de despesas de marketing: US $ 5,7 milhões em 2022

Canal de marketing	Despesas anuais
Marketing digital	US $ 2,1 milhões
Patrocínios da conferência médica	US $ 1,6 milhão
Mídia impressa e tradicional	US $ 2,0 milhões

Concord Medical Services Holdings Limited (CCM) - Modelo de negócios: fluxos de receita

Taxas de leasing de equipamentos médicos

A partir de 2024, a Concord Medical Services gera receita por meio de arrendamento de equipamentos médicos com os seguintes detalhes:

Categoria de equipamento	Receita anual de leasing	Duração média do arrendamento
Equipamento de diagnóstico de imagem	US $ 12,4 milhões	3-5 anos
Máquinas de radioterapia	US $ 8,7 milhões	4-6 anos

Encargos de serviço de diagnóstico

RECUTO DE RECEITAS DE SERVIÇO DE DIAGNÓSTICO:

• Serviços de imagem: US $ 24,6 milhões
• Teste de laboratório: US $ 16,3 milhões
• Procedimentos de diagnóstico especializados: US $ 9,2 milhões

Contratos de integração de tecnologia

Detalhes da receita de integração de tecnologia:

Tipo de contrato	Receita anual	Número de contratos
Sistemas de TI do hospital	US $ 15,8 milhões	42 contratos
Plataformas de telemedicina	US $ 7,5 milhões	28 contratos

Retornos de investimento em saúde

Desempenho do portfólio de investimentos:

• Portfólio de investimentos totais: US $ 87,6 milhões
• Retornos anuais de investimento: 6,3%
• Investimentos em capital de risco de saúde: US $ 22,4 milhões

Receitas de serviço de manutenção e suporte

Estrutura de receita do serviço de manutenção:

Categoria de serviço	Receita anual	Cobertura de serviço
Manutenção de equipamentos médicos	US $ 11,2 milhões	Contratos anuais abrangentes
Serviços de suporte técnico	US $ 6,7 milhões	Suporte remoto e no local 24/7

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Value Propositions

Concord Medical Services Holdings Limited delivers value through specialized, advanced oncology services across its network of self-owned and partnered cancer hospitals and clinics in China. The company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services.

Access to China's first-mover advanced proton therapy for complex cancers

The commitment to advanced technology is evidenced by the operationalization of proton therapy. A subsidiary, Concord Healthcare Group Co., Ltd., announced the completion of China's first proton therapy for Choroidal Malignant Melanoma on July 14, 2025. Furthermore, the official release of the Proton Therapy Large Model occurred on May 29, 2025. The commencement of proton therapy operations at Guangzhou Concord Cancer Hospital directly contributed to the hospital business net revenues increasing by 11.1% in the first half of 2025, reaching RMB153.0 million (US$21.4 million).

Full-cycle, multidisciplinary cancer care (diagnosis to prevention)

Concord Medical Services Holdings Limited features a full cycle of premium oncology services. This comprehensive approach covers:

• Cancer diagnosis.
• Treatment.
• Education.
• Prevention.

The company operates through its network of self-owned and partnered hospitals and clinics across China.

Differentiated accessibility to high-quality, imported pharmaceuticals

The company is striving to expand patient access to innovative medications. While specific figures for imported pharmaceutical sales in 2025 aren't detailed, the overall business structure includes medicine sales. The company's commitment is to expand patient access to these advanced therapeutic technologies.

High-touch, premium medical service benchmarked against international standards

Concord Medical Services Holdings Limited equips its cancer hospitals with technologically advanced equipment, such as the state-of-the-art proton therapy system, to enhance the quality of care. The focus on operational efficiency and cost reduction in H1 2025 helped improve the gross loss margin to 2.1% from 19.0% year-over-year, showing structural improvements in service delivery efficiency. The company aims to expand patient access to internationally advanced diagnostic and therapeutic technologies.

Improved patient outcomes by avoiding radical procedures like enucleation

The value proposition centers on providing advanced radiotherapy and diagnostic imaging services. The focus on precision radiotherapy, like proton therapy, is intended to strengthen patient confidence. The company is committed to advancing proton therapy, which is generally associated with less invasive treatment options for complex cancers.

Here's a quick look at the financial context supporting the delivery of these value propositions in the first half of 2025:

Metric	H1 2025 Value	Comparison/Context
Total Net Revenues	RMB200.6 million (US$28.0 million)	8.3% decrease from H1 2024 (RMB218.8 million).
Hospital Business Net Revenues	RMB153.0 million (US$21.4 million)	11.1% increase from H1 2024 (RMB137.8 million), driven by proton therapy.
Network Business Net Revenues	RMB47.6 million (US$6.6 million)	41.3% decrease from H1 2024 (RMB81.0 million).
Gross Loss Margin	2.1%	Significant improvement from 19.0% in H1 2024.
Net Loss Attributable to Shareholders	RMB27.1 million (US$3.8 million)	Substantial reduction from RMB172.3 million in H1 2024.
Adjusted EBITDA	Negative RMB62.2 million (US$8.7 million)	Improvement from negative RMB148.0 million in H1 2024.

The company's operational focus is clearly shifting value toward the hospital segment, where the advanced proton therapy services reside. The reduction in net loss to RMB27.1 million (US$3.8 million) in H1 2025 shows progress in monetizing these high-value services. Still, the network business saw revenues drop by 41.3% to RMB47.6 million (US$6.6 million).

Finance: draft 13-week cash view by Friday.

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Customer Relationships

You're looking at how Concord Medical Services Holdings Limited (CCM) keeps its clients close and engaged, which is key when you're dealing with premium, complex cancer care. The relationship model here is clearly built on high-touch service delivery, especially as they push into high-end technology like proton therapy.

High-touch, personalized care model for premium oncology services

The focus is on delivering specialized, hands-on care. This is the core of the hospital business segment, which saw net revenues of RMB153.0 million (US$21.4 million) in the first half of 2025, an increase of 11.1% year-over-year. This revenue growth in the hospital segment, which includes the Guangzhou Concord Cancer Hospital, suggests that the premium service model is gaining traction, even as total net revenues for H1 2025 were RMB200.6 million (US$28.0 million). The commitment to personalized plans, which adhere to international and domestic guidelines like NCCN and CSCO, is a major part of this high-touch approach. Also, case managers offer one-on-one assistance to streamline the medical process for patients. It's about making a difficult journey manageable.

Long-term clinical support and joint diagnosis for network partners

For the broader network, which historically involved centers in 20 hospitals across 13 provinces, the relationship is one of deep collaboration, not just transactional leasing. Concord Medical Services Holdings Limited provides clinical support services to doctors working in its network centers. This support includes developing treatment protocols for those doctors and organizing joint diagnosis between doctors in the network and clinical research. Long-term clinical support and joint diagnosis for network partners is a way to embed Concord Medical's expertise directly into the partner facilities. The network business revenue, however, saw a significant drop to RMB47.6 million (US$6.6 million) in H1 2025, a decrease of 41.3% compared to H1 2024, which you'll definitely want to watch.

• Clinical support includes developing treatment protocols.
• Organizing joint diagnosis between network doctors.
• Leveraging extensive network of domestic and international experts.

Continuous patient education and prevention programs

Concord Medical Services Holdings Limited profiles itself as a provider of a full cycle of services, which explicitly includes cancer education and prevention. While specific 2025 metrics on program attendance or reach aren't immediately available, this function is crucial for building long-term patient trust and driving early diagnosis, which feeds the premium service pipeline. They are striving to enhance public understanding of precision radiotherapy as part of their forward-looking strategy.

Technology-enabled engagement via the Proton Therapy Large Model

The introduction of advanced technology directly shapes customer interaction and perceived value. Concord Healthcare announced the official release and successful deployment of its self-developed large language model (LLM) focused on proton therapy in May 2025 at the Guangzhou Concord Cancer Hospital. This Proton Therapy Large Model was constructed using multimodal medical data that integrates nearly 10,000 high-quality radiotherapy cases. The deployment followed the completion of China's first proton therapy for Choroidal Malignant Melanoma in July 2025, showing the technology is moving from development to direct patient application. This model is designed to enhance precision and patient outcomes, which is a powerful relationship tool for attracting patients seeking the most advanced care.

Here's a quick look at some key operational and financial data points from the first half of 2025 that frame these customer-facing efforts:

Metric	Value (H1 2025)	Comparison/Context
Total Net Revenues	RMB200.6 million (US$28.0 million)	8.3% decrease vs. H1 2024
Hospital Business Net Revenues	RMB153.0 million (US$21.4 million)	11.1% increase vs. H1 2024
Network Business Net Revenues	RMB47.6 million (US$6.6 million)	41.3% decrease vs. H1 2024
Gross Loss Margin	2.1%	Improved from 19.0% in H1 2024
Proton Therapy LLM Training Data Integration	Nearly 10,000 cases	Used for model enhancement

The shift in revenue mix, with the hospital segment growing while the network segment shrinks, definitely points to where the company is focusing its high-touch, technology-driven customer relationships.

Finance: draft 13-week cash view by Friday.

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Channels

You're looking at how Concord Medical Services Holdings Limited (CCM) gets its premium oncology services-from proton therapy to diagnostics-into the hands of patients as of late 2025. The channels are clearly bifurcated, reflecting the company's strategic pivot away from its legacy network model toward owning and operating its own high-tech facilities.

The performance of these channels is best seen through the H1 2025 revenue split. The Hospital Business, which represents the self-owned facilities, is the clear growth engine, while the Network Business, representing partnered centers, is shrinking its revenue contribution significantly.

Channel/Business Segment	H1 2025 Net Revenue (RMB)	H1 2025 Net Revenue (US$)	Year-over-Year Change (H1 2024 vs H1 2025)
Self-owned/Hospital Business	RMB 153.0 million	US$ 21.4 million	+11.1%
Network Business (Partnered)	RMB 47.6 million	US$ 6.6 million	-41.3%
Total Net Revenues	RMB 200.6 million	US$ 28.0 million	-8.3%

The self-owned specialty cancer hospitals are where the high-end, capital-intensive services are centered. Guangzhou Concord Cancer Hospital is the prime example here; its commencement of proton therapy operations was the main driver for the Hospital Business revenue growth of 11.1% in the first half of 2025. This facility is key to delivering multidisciplinary cancer care, including advanced technologies like the state-of-the-art proton therapy system. The company is focusing its capital expenditure here to control the patient experience end-to-end.

The network of partnered hospitals for radiotherapy/imaging centers represents the legacy channel, now showing a sharp decline. While Concord Medical Services Holdings Limited historically operated the largest network of radiotherapy and diagnostic imaging centers in China through long-term arrangements with top-tier hospitals, the H1 2025 revenue from this segment fell by 41.3% to RMB 47.6 million (US$6.6 million). This segment involves providing equipment and managing daily operations on the premises of these hospital partners.

Regarding patient acquisition, the channels rely on a mix of direct and indirect sourcing, though specific 2025 referral numbers aren't public. The growth in the Hospital Business suggests strong direct patient flow, likely driven by the reputation of facilities like the Guangzhou Hospital and the successful deployment of cutting-edge treatments, such as the completion of China's first proton therapy for Choroidal Malignant Melanoma in July 2025. The company's overall strategy is to expand patient access to these advanced technologies.

For online and digital platforms, the focus appears to be on corporate communication and service announcements rather than direct patient booking, based on recent press releases. The company uses its investor relations website and SEC filings to communicate operational milestones, such as the official release of the Proton Therapy Large Model in May 2025. You can expect outreach efforts to be concentrated on enhancing public understanding of precision radiotherapy, which supports patient confidence and, indirectly, patient referrals to their physical centers.

Here's a quick look at the channel focus:

• Self-owned Hospitals: Primary revenue driver, showing 11.1% H1 2025 growth.
• Partnered Centers (Network): Declining revenue contribution, down 41.3% in H1 2025.
• Key Asset: Guangzhou Concord Cancer Hospital, a hub for proton therapy.
• Digital Role: Primarily for corporate updates and building public awareness.

If onboarding new cooperative centers proves difficult, the reliance on the self-owned hospital channel will only intensify.

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Customer Segments

You're looking at a company in the middle of a major pivot, moving away from its older leasing model toward owning and operating high-margin specialty facilities. This shift directly targets high-net-worth patients seeking premium, advanced cancer treatment in China. The financial results for the first half of 2025 clearly show where the value is now coming from.

Here's the quick math on the revenue split for the six months ended June 30, 2025, which really highlights this customer focus:

Customer Segment Focus	H1 2025 Net Revenue (RMB)	H1 2025 Net Revenue (USD)	Year-over-Year Change
Hospital Business (Premium/Specialty)	RMB153.0 million	US$21.4 million	11.1% increase
Network Business (Equipment/Services)	N/A (Revenue Plummeted)	N/A	41.3% decrease
Total Company Net Revenues	RMB200.6 million	US$28.0 million	8.3% decrease (Total)

The focus on specialized treatment, particularly proton therapy, is a key differentiator for attracting these premium patients. For instance, the Guangzhou Concord Cancer Center, a subsidiary, completed China's first proton therapy treatment for a patient with choroidal malignant melanoma on July 11, 2025. That kind of first-in-market capability supports the higher pricing structure you'd expect for this service. Also, the underlying technology development is data-intensive; their proprietary proton therapy Large Language Model integrates nearly 10,000 high-quality radiotherapy cases for training. That's serious data depth.

The patient profiles driving this premium segment include:

• High-net-worth individuals seeking advanced oncology care.
• Patients requiring highly specialized treatment like proton therapy.
• Patients with complex or rare malignancies, such as choroidal malignant melanoma.

Then you have the other core segment: domestic Chinese hospitals that rely on Concord Medical Services Holdings Limited for the Network Business's equipment and services, though that segment is clearly under pressure right now. Historically, this network was quite extensive, showing the depth of their prior relationships. What this estimate hides, though, is the current number of active hospital partners as of late 2025, as the latest public data is from the end of 2020.

To give you context on the scale of those hospital partnerships that feed the Network Business:

Network Component	Count (As of Dec 31, 2020)	Geographic Scope
Total Radiotherapy/Diagnostic Centers	27 centers	Spanning over 20 cities
Partner Hospitals Hosting Centers	20 hospitals	Across 13 provinces/regions in China
Company Employees (Total)	595	As of late 2025

Finance: draft 13-week cash view by Friday.

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Cost Structure

You're looking at where Concord Medical Services Holdings Limited (CCM) is spending its cash to keep the lights on and, more importantly, to build out that advanced cancer care network. The cost structure is heavily weighted toward asset acquisition and the fixed costs of running high-tech hospitals.

The capital expenditure side is defintely a major drain, reflecting the commitment to high-end technology like proton therapy. For the first half of 2025, capital expenditures totaled RMB100.6 million (US$14.0 million). This was actually lower than the prior year's RMB168.4 million, mainly due to a decrease in deposits for equipment and construction fees for the hospital business. Still, the underlying cost of acquiring and maintaining that state-of-the-art equipment, like the proton therapy systems in Guangzhou and planned for Shanghai and Chengdu, is substantial.

Operating expenses show where the day-to-day running costs lie. General and administrative expenses were RMB119.4 million (US$16.7 million) for the six months ended June 30, 2025. This figure was down from RMB131.2 million in the same period last year, showing some success in cost-cutting efforts.

Here's a quick look at some of the key H1 2025 cost components, all in millions of RMB:

Cost Category	Amount (H1 2025)	Notes
Costs of Revenues (Hospital Business)	RMB157.2 million	Down 9.6% from H1 2024 due to improved HR efficiency and lower consumables/lease costs.
General and Administrative Expenses	RMB119.4 million	Includes staff costs and listing expenses.
Employee Benefit Expenses (within G&A)	RMB51.0 million	A significant portion of the G&A spend.
Selling Expenses	RMB21.0 million	Down from RMB25.0 million in H1 2024.

The investment in future capabilities, specifically around AI and clinical protocols, is a strategic cost. Concord Medical Services Holdings Limited launched its proprietary large language model (LLM) for proton therapy in May 2025 at its Guangzhou Concord Cancer Hospital. This system analyzes over 10,000 high-quality radiotherapy cases, multimodal medical data, and academic literature to optimize tumor targeting.

The costs associated with developing and deploying this technology, alongside refining specialized treatment protocols, are embedded within the overall operating structure. You see the output of this R&D focus in the hospital business, which is now operational with specialized protocols for various malignancies.

The cost structure also reflects the two main segments of the business:

• Costs of revenues for the Network Business were RMB47.7 million (US$6.7 million) in H1 2025.
• This was a 44.8% decrease from RMB86.4 million in H1 2024, linked to reduced sales and installation of medical equipment and software.

Finance: draft 13-week cash view by Friday.

Concord Medical Services Holdings Limited (CCM) - Canvas Business Model: Revenue Streams

You're looking at how Concord Medical Services Holdings Limited (CCM) brings in cash as of late 2025. Honestly, the revenue picture for the first half of 2025 shows a slight dip in total intake, coming in at RMB200.6 million (or US$28.0 million) for the six months ending June 30, 2025. That was down an 8.3% compared to the same period last year. The real story, though, is the shift within the business lines. The hospital segment is actually showing strength, partly because they kicked off proton therapy operations at Guangzhou Concord Cancer Hospital.

Here's the quick math on the two main reported revenue segments for H1 2025:

Revenue Stream Segment	H1 2025 Net Revenue (RMB)	H1 2025 Net Revenue (US$)
Hospital Business services	RMB153.0 million	US$21.4 million
Network Business revenue	RMB47.6 million	US$6.6 million

The hospital business is definitely the core focus now, driving that 11.1% increase in its segment revenue for the first half of 2025, even as the network business saw a significant drop of 41.3%. Still, you need to keep an eye on all the ways Concord Medical Services Holdings Limited (CCM) generates income, as the other streams contribute to the overall top line.

Beyond the reported segments, the revenue model includes several other key areas:

• Proton therapy treatment fees: This is noted as a high-margin, growing segment, directly impacting the RMB153.0 million hospital revenue.
• Sales of high-end, original and imported pharmaceuticals
• Diagnostic imaging and other treatment services fees